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Introduction
Glanzmann thrombasthenia (GT) is a rare, autosomal recessive bleeding disorder characterized by a life-long mucocutaneous bleeding tendency and absent or severely reduced platelet aggregation in response to the physiological agonists ADP, epinephrine, and collagen, but relatively normal aggregation in response to ristocetin [1] [2] [3] . The disease is caused by either a lack or dysfunction of the platelet integrin a IIb b 3 (glycoprotein IIb/IIIa), which serves as a receptor for fibrinogen, von Willebrand factor, and perhaps other adhesive glycoproteins [4] . Mutations in either the a IIb or b 3 genes have been identified in more than 100 patients with GT, and include minor or major deletions, insertions, inversions, and point mutations [5] [6] [7] [8] . a IIb and b 3 are synthesized as two independent polypeptide chains and enter the endoplasmic reticulum (ER) where they form a complex, undergo N-linked glycosylation and form intrachain disulphide bonds [9] . The complexes are then transported to the Golgi apparatus for final oligosaccharide processing and cleavage of a IIb into heavy and light chains, before being transported to the membranes of a granules and the plasma membrane [10] . The assembly of the a IIb b 3 complex appears to be a prerequisite for transport out of the ER and thus cell surface expression [11, 12] . a IIb that is not complexed to b 3 is likely retained in the ER and degraded, while the uncomplexed b 3 can either be degraded or combine with an aV subunit to form the vitronectin receptor, aVb 3 [13] .
Mutations that impair the synthesis of either a IIb or b 3 prevent the export of sufficient numbers of a IIb b 3 complexes to the platelet surface resulting in GT [1] . However, a IIb or b 3 mutations that have no apparent effect on the synthesis of either subunit can also give rise to thrombasthenia, either by perturbing the conformation of pro-a IIb b 3 complexes so they fail to be exported out of the ER [14] [15] [16] [17] [18] [19] [20] [21] or by impairing a IIb b 3 function [22] [23] [24] [25] [26] [27] [28] . So far, 20 missense mutations causing GT have been reported within the b-propeller domain of a IIb , the region that both complexes with b 3 and contributes to the ligand binding site. Thirteen of these mutations were associated with reduced surface expression, of which six mutations namely, G242D [15] , V298F [20] , E324K [19] , R327H [16] , I374T [20] , and G418D [14] were directly demonstrated to disrupt biogenesis by preventing transport of pro-a IIb b 3 from the ER to the Golgi, leading to intracellular retention. In this paper, we describe three new missense mutations, G128S, S287L and G357S within a IIb b-propeller blades 2, 5 and 6; all three are located on the upper face of propeller in the area involved in interaction with b 3 . We show that all three mutant pro-a IIb were synthesized, stable and able to form a complex with b 3 . The G128S mutation completely prevents the transport of the pro-a IIb b 3 complex from the ER to the Golgi, whereas the S287L and G357S mutations variably impair transport from the ER to the Golgi and subsequent surface expression.
Patients
Patient 1, from Andhra Pradesh, was diagnosed as having GT at 4 years of age based on a history of easy bruising, epistaxis, prolonged bleeding time (more than 15 min), absent clot retraction, and absent in vitro platelet aggregation in response to ADP, epinephrine, and collagen. His parents were firstdegree relatives (uncle-niece), but had no bleeding symptoms. Patient 2, also from Andhra Pradesh, was diagnosed at 5 years of age based on a history of epistaxis, gum bleeding, hematuria, reduced clot retraction, and absent in vitro platelet aggregation in response to ADP, epinephrine, and collagen, but a normal initial phase response to ristocetin. His parents were also first-degree relatives (uncle-niece) and had no bleeding symptoms. Patient 3, from Tamil Nadu, had more mild symptoms (gingival bleeding) and was diagnosed at 21 years of age based on prolonged bleeding time (more than 15 min), absent in vitro platelet aggregation in response to ADP, epinephrine, and collagen, but a normal initial phase response to ristocetin. His parents had no significant bleeding symptoms, but two of his paternal aunts died of bleeding complications before 10 years of age. There was no known consanguinity.
Materials and methods

Immunoblot analysis of platelet lysates
Immunoblot analysis of washed platelets was performed essentially as previously described [29] using murine mAbs specific for a IIb (CD41, SZ22) and b 3 (CD61, SZ21) [Immunotech, Marseille, Cedex, France]. Samples for a IIb were tested reduced to display both pro-a IIb and the heavy chain of mature (cleaved) a IIb , and samples for b 3 were tested nonreduced.
Polymerase chain reaction, single strand conformation polymorphism analysis and DNA sequencing A total of 38 polymerase chain reaction (PCR) reactions were performed on genomic DNA extracted from buffy coat cells using intragenic primers and conditions that were previously described [30, 31] and additional primers and conditions that can be obtained by contacting one of us (B.S.C). Single strand conformation polymorphism (SSCP) analysis was performed by either an automated (PhastGel System; Pharmacia Biotech, Uppsala, Sweden) or manual method (Protean II Cell; BioRad, Hercules, CA, USA). DNA sequencing was performed on amplicons that showed mobility shifts by SSCP analysis (Big Dye terminator kit; PE Biosystems, Foster City, CA, USA).
Site-directed mutagenesis
Mutant a IIb cDNA constructs were generated by site-directed mutagenesis (QuikChange XL Site-Directed Mutagenesis Kit; Stratagene, La Jolla, CA, USA). Wild-type a IIb cDNA in the pEF1/V5-His mammalian expression vector was used as the template (kindly provided by Dr Junichi Takagi, Harvard University, Boston, MA, USA). After mutagenesis, the mutant cDNA was used to transform XL10-Gold ultracompetent cells as per the manufacturer's instructions (Stratagene).
Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were grown in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 1% non-essential amino acids (GIBCO, Carlsbad, CA, USA), and 1% each of penicillin and streptomycin. Cells were grown to 70-80% confluency and then transfected with vector alone (mock), or normal a IIb cDNA alone (about 7.5 lg), or normal or mutant a IIb cDNA (about 7.5 lg) co-transfected with an equal amount of normal b 3 cDNA in pcDNA 3.1/Myc-His vector (also provided by Dr Takagi) (Perfectin Transfection Reagent; Gene Therapy Systems, San Diego, CA, USA). Forty-eight hours after transfection, stable cell lines were generated by G418 selection (0.5 mg/ mL, GIBCO) for 14 days. To ensure comparability among cell lines, stable cell lines were not selected for high surface a IIb b 3 expression. Cells were then harvested and solubilized; after preclearing the lysates with protein G beads, 2 lg of anti-V5 tag antibody was added, followed by protein G beads. The beads were washed twice and immunoprecipitates were eluted in SDS sample buffer containing 10% b-mercaptomethanol. After SDS-PAGE, gels were fixed, washed, soaked in an autoradiographic image intensifying reagent (Autoflour; National Diagnostics, Atlanta, GA, USA), dried, and subjected to autoradiography.
Immunofluorescence microscopy
Transfected cells were grown overnight in DMEM on poly-L-lysine-coated glass cover slips, washed twice, and fixed in ice-cold acetone-methanol (1:1). The cells were washed, incubated in blocking solution [2.5% bovine serum albumin (BSA)/0.05% NP-40 in PBS] and reacted with either rabbit anti-calnexin polyclonal antibody (ER marker, 1:200 dilution; Stressgen Bioreagents, Victoria, BC, Canada) or rabbit anti-mannosidase II polyclonal antibody (Golgi marker, 1:100 dilution; US Biological, Swampscott, MA, USA), followed by labeling with TRITC-conjugated F(ab¢) 2 fragment of goat anti-rabbit IgG (H + L) (Jackson Immunoresearch Laboratories, West Grove, PA, USA). The cells were washed thrice and then incubated with a 1:100 dilution of FITC-conjugated anti-a IIb antibody (SZ22). The cover slips were then washed, air-dried, mounted onto a glass slide with antifade solution (Molecular Probes, Eugene, OR, USA), and analyzed using an inverted microscope (Olympus 1X70, Melville, NY, USA). Images were deconvolved using Deltavision software (Applied Precision, Issaquah, WA, USA).
Results
Platelet content of a IIb b 3
Immunoblot analysis of platelet lysates showed no detectable pro-a IIb or mature a IIb in any of the patient samples; trace amounts of b 3 were detected only in samples from patients 2 and 3, but no b 3 was detectable in the sample from patient 1 (data not shown).
Mutation detection
The SSCP analysis of the genomic DNA of patient 1 revealed a mobility shift in the PCR product of exon 4 of a IIb and DNA sequencing confirmed a G fi A nucleotide substitution at position 475 of the pro-a IIb sequence. This predicts a substitution of glycine to serine at amino acid position 128 within the b-propeller domain at the end of the S3-S4 loop of blade 2, just before the third b strand (W2S3) [32, 33] . In patient 2, a mobility shift was observed in the PCR product of exon 11 of a IIb , and this was found to be a result of C fi T nucleotide substitution at position 953 of the pro-a IIb sequence. This predicts a substitution of serine to leucine at amino acid position 287, which is located in the b-propeller domain just before the beginning of the first b strand in blade 5 (W5S1). In patient 3, a mobility shift was observed in the PCR product of exon 12 of a IIb and a G fi A nucleotide substitution at position 1162 of the proa IIb sequence was subsequently identified. This predicts a substitution of glycine to serine at amino acid position 357, which is also located in the b-propeller domain, in the highly conserved region just before the first b strand in blade 6 (W6S1). Fig. 2A ). Cells transfected with normal a IIb alone gave a pattern of pro-a IIb synthesis and disappearance very similar to the cells co-transfected with both normal a IIb and b 3 , with no obvious evidence of more rapid degradation. Pro-a IIb molecules were also synthesized at the normal rate by the three mutant a IIb b 3 cells, but there was no progression to mature a IIb in the G128S mutant, only trace progression to mature a IIb in the S287L mutant, and slightly more progression to mature a IIb in the G357S mutant ( Fig. 2A) . Of note, the small amounts of mature a IIb observed in the S287L and G357S mutants appeared very early in the time course and did not increase thereafter in density. The rates of disappearance of pro-a IIb in the three mutant cells were very similar to the rates in the cells expressing a IIb alone and normal a IIb b 3 , with a half-disappearance time of approximately 4 h (Fig. 2B) . In contrast to cells transfected with normal a IIb b 3 , however, all three mutant cells showed some increase in relative pro-a IIb values over the first 2 h. Thus, despite their defects in progression to mature a IIb , the G128S, S287L and G357S mutations did not affect either the production of pro-a IIb or its rate of degradation. (Fig. 2C) . The pro-a IIb b 3 complexes of all three mutants were also detected up to 8 h postchase in a separate experiment (data not shown). (Fig. 3A , left top and bottom panels). The ER (calnexin) stain was distributed diffusely throughout the cell in clusters that were more accentuated near the periphery (Fig. 3A, top center panel) , while the Golgi (mannosidase II) stain was present in more discrete clusters, primarily in the periphery (Fig. 3A , bottom center panel). The merged image of a IIb and calnexin demonstrated extensive co-localization, seen as yellow, indicating the presence of a IIb in the ER (Fig. 3A, top right  panel) . The cell surface a IIb b 3 , however, appeared green, indicating that it did not co-localize with the calnexin stain, and thus served as a control. In the normal a IIb b 3 cells, a IIb stain also co-localized with the mannosidase-II stain (Fig. 3A , bottom right panel), indicating the presence of a IIb in the Golgi. The insert figures in Fig. 3A are from mock transfected cells demonstrating the absence of a IIb , but the presence of calnexin-and mannosidase-II positive organelles. The G128S mutant showed enhanced staining for a IIb in a ring-like configuration within the cell, but no surface a IIb staining (Fig. 3B , left top and bottom panels). Co-localization with calnexin ( Fig. 3B , top center and right panels) indicated that the vast majority of the a IIb was in the ER. In the a IIb and mannosidase-II merged image, the mannosidase-II-positive organelles stained red rather than yellow, indicating little or no presence of G128Sa IIb b 3 in the Golgi (Fig. 3B , bottom center and right panels). The S287L mutant cells demonstrated barely detectable surface labeling for a IIb , strong ring-like staining for a IIb inside the cell that co-localized with calnexin, indicating an ER localization, and some co-localization with mannosidase-II (Fig. 3C) . In contrast, a small amount of surface a IIb was detectable in the G357S mutant cells and there was stronger co-localization with mannosidase-II, indicating that more G357Sa IIb b 3 was transported to the Golgi. The strong ring-like staining for a IIb , which co-localized with calnexin was also observed in these cells, indicating the presence of G357S a IIb in the ER (Fig. 3D) . Locations of the three mutations in the crystal structure of a IIb b 3 and their potential structural implications
The locations of the a IIb b-propeller mutations, G128S, S287L, and G357S were identified on the crystal structure of a IIb b 3 [33] using the MOLecule analysis and MOLecule display (MOLMOL) software. The residues glycine 128 and serine 287 are at the top of the propeller and lie within the interface with the bA domain of b 3 , while the glycine 357 is buried deeper within the propeller structure (Fig. 4A ). All three mutations are located among the residues contributing to the highly conserved ÔcageÕ motif, which consists of two concentric rings of predominantly aromatic residues within the b-propeller structure [32] . This motif has been shown to contain a consensus sequence, (X 17)33 -{//G/X 13)20 PX 2)15 GX 5)8 }) 7 , where X is any residue and / is an aromatic residue (Fig. 4B ) [32] . It is defined by a mostly aromatic 4-residue ÔcupÕ (//G/) that precedes the first b strand in each propeller blade (A), a proline immediately following the second b strand (B), referred to as Pro-B, and an invariant glycine at the beginning of the third b strand (C), referred to as Gly-C [32] . Glycine 128 is located at the position of the invariant glycine in blade 2. The conservation of glycine at this or an adjacent relative location in all seven b-propeller blades of a IIb , aV, a1-a11, aM, aL, and aX subunits in humans indicates the importance of having the small size and/or flexibility of glycine in this region. The serine 287 is located immediately adjacent to the //G/ ÔcupÕ in blade 5, and is conserved in a1, a2, a4-a11, aL, and aX subunits in humans. The glycine 357 is located directly within the ÔcupÕ of blade 6 and is conserved in aV, a1-a11, aL, aM, and aX subunits in humans. Of especial note, a previously described GT mutation (G418D) is in the same position as glycine 357 in the ÔcupÕ of a IIb blade 7 [14] . The three mutated a IIb residues are also conserved across species, including a IIb of mouse, rat, rabbit, horse, pig, and dog.
Discussion
We have characterized three separate a IIb mutations in the b-propeller domain, in blades 2 (G128S), 5 (S287L), and 6 (G357S), in three unrelated patients with GT from southern India. The pro-a IIb of the G128S mutant was synthesized in HEK 293 cells and formed a complex with b 3 but we could not mature, cleaved a IIb . Although HEK 293 cells differ from megakaryocytes, our data indicating the need for pro-a IIb b 3 transport to the Golgi as a prerequisite for processing of pro-a IIb to mature a IIb are similar to those previously reported in megakaryocytes [10] . The S287L and G357S mutations in patients 2 and 3 respectively, resulted in abnormalities similar to those in patient 1, but the defects in a IIb b 3 complex formation, transport to the Golgi, and surface expression were less severe. Of note, the pro-a IIb in all three mutations was synthesized and disappeared with kinetics that were similar to normal pro-a IIb when expressed either alone or in combination with normal b 3 . Similar observations have been made with other mutations affecting the a IIb b-propeller domain [14, 15] . Moreover, as the overall disappearance of pro-a IIb from cells lacking b 3 is not more rapid than in cells containing normal b 3 , these data suggest that the rate of proa IIb degradation is not primarily determined by the formation of the pro-a IIb b 3 complex. Immunoprecipitation with anti-b 3 antibody detected only a small amount of pro-a IIb in complex with b 3 in cells expressing normal and mutant a IIb b 3 receptors.
The availability of the crystal structures of aVb 3 and a IIb b 3 permits us to correlate the molecular abnormalities in the a IIb b-propeller domain in GT patients with their functional consequences [32, 33] b-propeller mutations causing Glanzmann thrombasthenia 2779 a IIb b 3 in Fig. 5A ,B. The vast majority of the missense mutations that have been characterized result in decreased or absent a IIb b 3 surface expression. The two missense mutations that affect ligand binding (Y143H [27] and P145A [26] ) are located adjacent to the a IIb -specific cap domain that has been implicated in ligand binding [33] . Many of the other mutations are at the interface between the a IIb bpropeller domain and the b 3 bA-domain, where one might have expected them to interfere with complex formation between pro-a IIb and b 3 . However, in our studies [20] and in studies conducted by others [14] [15] [16] [17] 19, 24, 28] [24] , and the G128S that we now report), only the F171C mutation resulted in failure to form the pro-a IIb b 3 complex, and even in this case it is uncertain whether this resulted from it selectively altering the interface between pro-a IIb and b 3 or from it causing more general disruption of pro-a IIb folding as a result of the introduction of a new unpaired cysteine residue. Several a IIb b-propeller mutations affect the regions in blades 4-7 that are near to or in the b-hairpin calcium binding loops [14] [15] [16] [17] 19] . These mutations also do not affect pro-a IIb b 3 complex formation, but dramatically affect receptor maturation and surface expression. The major limiting step in a IIb b 3 biogenesis in the mutations we describe and most of the previously described mutations is not, therefore, complex formation, but rather transport from the ER to the Golgi for carbohydrate modification, pro-a IIb cleavage, and transport to the cell surface. It is likely, therefore, that a molecular mechanism exists to assess the quality of the folding of pro-a IIb and/or the conformation of the pro-a IIb b 3 complex as a prelude to transport out of the ER. Direct support for alterations in the conformation of the pro-a IIb b 3 complex as a result of a number of the reported mutations (V298F, I374T, G242D, and G418D) derives from studies demonstrating lack of binding of monoclonal antibodies that are a IIb b 3 complex-specific or conformation-specific to the mutant proteins [14] [15] [16] . It is unlikely that the quality control mechanism involves a ligand-like molecule as some mutations that profoundly affect ligand binding do not result in markedly reduced receptor expression, as for example, b 3 D119Y [22, 35] and R214Q [36, 37] . Alterations in binding to a chaperone-like protein(s) seem likely. 
